Walder Wyss advised Merck on the deal, and Baker Mckenzie advised Chord Therapeutics SA. Merck entered into an agreement to acquire Chord Therapeutics SA, a Swiss-based...
You must be a Standard 1 Year member to access this content.
VISCHER advised Anjarium Biosciences on the deal. Baker McKenzie advises a consortium of life science funds, including Abingworth and Gimv, alongside Omega Funds, Pfizer Ventures and...
You must be a Standard 1 Year member to access this content.
Baker McKenzie advised Artum AG on the transaction. Artum AG, the leading Swiss industrial holding company, completed the sale of 100% of their shares to Storskogen....
You must be a Standard 1 Year member to access this content.
Baker McKenzie advised Numab Therapeutics on the deal. Numab Therapeutics closed a CHF 100 million (approximately USD 110 million) Series C financing. Numab Therapeutics is a clinical...
You must be a Standard 1 Year member to access this content.
